健世科技(09877.HK)LuX-Valve Plus关键性注册临床试验获美FDA批准

阿斯达克财经
Feb 08

健世科技-B(09877.HK) 公布,公司自主研发的经血管三尖瓣介入置换系统LuX-Valve Plus,正式获美国食品及药品监督管理局“FDA”对其关键性注册临床试验的无附加条件的试验用器械豁免批准, 标志该产品在美国的注册临床进程及集团全球化战略取得重要突破性进展。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2026-02-06 16:25。)AASTOCKS新闻

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10